Prohost Letter #435
The Value of the Biotech Companies
A Continuation of Prohost Letter #434
A Recap
The biotech near and long-term values, we insist, must be based on the firms’ scientific capabilities, products’ potentials and financial results. In the past months the stocks evaluations by bloggers, and some assessors, have been tailored to mislead investors into serving the purposes of the manipulators’ weird agendas. In the past issue we wrote about the unfair downgrades of accomplished biotech firms, including those whose quarterly financial results have beaten analysts’ exaggerated expectations. We wrote about the sell-side bloggers who keep . . .